OXURION NV (OXUR.BR)       0.32  +0.01 (+1.91%)

0.32  +0.01 (+1.91%)

BE0003846632 - Common Stock


Fundamental Rating

We assign a fundamental rating of 1 out of 10 to OXUR. OXUR was compared to 49 industry peers in the Biotechnology industry. Both the profitability and financial health of OXUR have multiple concerns. OXUR has a expensive valuation and it also scores bad on growth




Profitability

Profitability Rating


The profitability ratios for OXUR are negative, so there is not much use analyzing them.
OXUR has a Return On Assets of -154.47%. This is below the industry average of -33.16%. 100% of the industry peers outperform OXUR.

OXUR's Profit Margin of -2584.93% is worse than the rest of the industry. The industry average Profit Margin is -178.28%. 92% of the industry peers have a better Profit Margin.
OXUR has a very weak Piotroski-F score of 1.00. This is an indication of health and profitability issues for OXUR.
VS Industry

ROA (-154.47%) VS Industry: 0% outperformed.

-154.47
121.18

Profit Margin (-2584.93%) VS Industry: 8% outperformed.

-470,040.00
78.59

Valuation

Valuation Rating


OXUR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for OXUR. No positive earnings are expected for the next year.
VS Industry

Growth

Growth Rating


Based on estimates for the next 5 years, OXUR will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.45% on average per year.
When comparing the Revenue growth rate of the last 5 years to the growth rate of the upcoming 5 years, we see that the growth is accelerating.
The earnings per share for OXUR have decreased by -6.60% in the last year.

Looking at the last year, OXUR shows a very negative growth in Revenue. The Revenue has decreased by -45.72% in the last year.
Measured over the past 5 years, OXUR shows a very negative growth in Revenue. The Revenue has been decreasing by -30.79% on average per year.
The Revenue is expected to decrease by -14.87% on average over the next 5 years. This is quite bad

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPSN/A N/A -6.6% 39.22% 27.98% -3.2% 14.45%
Revenue-30.79% -40.37% -45.72% -75.16% -50.16% -25.99% -14.87%

Health

Health Rating


With a Debt to Equity ratio of -7.86, OXUR is one of the better performing companies in its industry. It outperforms 100% of its industry peers.
OXUR has a Current Ratio of 1.23. This is a normal value and indicates that OXUR is financially healthy and should not expect problems in meeting its short term obligations.
OXUR has a Quick Ratio of 1.22. This is a normal value and indicates that OXUR is financially healthy and should not expect problems in meeting its short term obligations.
Compared to an average industry Current Ratio of 3.06, OXUR is worse placed to pay its short term obligations than its industry peers. 93% of its industry peers have a better Current Ratio.

When comparing the Quick Ratio of OXUR to the average industry Current Ratio of 2.73, OXUR is less able to pay its short term obligations than its industry peers. 91% of its industry peers have a better Quick Ratio.
Based on the Altman-Z score of -7.78, we must say that OXUR is in the distress zone and has some risk of bankruptcy.
When comparing the Altman-Z score of OXUR to the average industry Altman-Z score of -0.32, OXUR is less financially healthy than its industry peers. 93% of its industry peers have a better Altman-Z score.
OXUR has a very weak Piotroski-F score of 1.00. This is an indication of health and profitability issues for OXUR.
VS Industry

Debt/Equity (-7.86) VS Industry: 100% outperformed.

3.67
-7.86

Quick Ratio (1.22) VS Industry: 9% outperformed.

0.33
19.61

Current Ratio (1.23) VS Industry: 7% outperformed.

0.33
19.61

Altman-Z (-7.78) VS Industry: 7% outperformed.

-22.30
94.92

Dividend

Dividend Rating


No dividends for OXUR!.

OXUR Daily chart

OXURION NV0.32

EBR:OXUR (8/10/2022, 7:00:00 PM)+0.01 (+1.91%)

Chartmill FA Rating
GICS Sector Health Care
GICS IndustryGroup Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry Biotechnology
Earnings (Last) N/A N/A Earnings (Next) N/A N/A
Ins Owners N/A Inst Owners N/A
Market Cap 16.41M Analysts 44
Valuation
PE N/A Fwd PE N/A
PEG (NY) N/A PEG (5Y) N/A
P/S 14.54 P/B N/A
EV/EBITDA -0.7
Profitability
ROA -154.47% ROE N/A
PM -2584.93 Asset Turnover 0.06
Growth
EPS 1Y -6.6% EPS 3Y N/A
EPS 5Y N/A EPS growth Q2Q 8.06%
EPS Next Y 39.22% EPS Next 2Y 27.98%
EPS Next 3Y -3.2% EPS Next 5Y 14.45%
Revenue growth 1Y -45.72% Revenue growth 3Y -40.37%
Revenue growth 5Y -30.79% Revenue growth Q2Q -2.93%
Revenue Next Year -75.16% Revenue Next 2Y -50.16%
Revenue Next 3Y -25.99% Revenue Next 5Y -14.87%
Health
Current Ratio 1.23 Quick Ratio 1.22
Altman-Z -7.78 F-Score 1
Debt/Equity -7.86
Dividend
Dividend Yield N/A Dividend Growth N/A
DP N/A Ex-Date N/A

Fundamental Stock Screener Links

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the EuroNext

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the EuroNext

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the EuroNext

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the EuroNext